The article by Hayward and colleagues addresses one of the most common symptom presentations, and controversies, in medicine: a patient with a sore throat. In recent years, the reduction of unnecessary antibiotic use in all respiratory infections has become especially important to limit antibiotic resistance. The authors point out that "the pressure for clinicians to reduce antibiotic prescriptions for sore throats leaves a vacuum". As a result, the use of corticosteroids as an alternative treatment is appealing.
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The methods used in this meta-analysis were rigorous. An extensive search for high-quality studies was undertaken. Decisions about which studies were included and excluded were transparent and clear. High-quality statistical methods for combing data were applied, and the results are presented clearly. However, as in many meta-analyses, the authors are ultimately limited by the available studies and the outcomes these studies report. In this regard, the meta-analyses included eight small studies ranging in size from 51 to 184 patients, with a mix of children and adults. The total number of patients was 743, a small sample size not uncommon for primary care conditions but far smaller than many single studies of cardiovascular disease or cancer screening. In addition, as few as three or four studies report data for some outcomes.
Do the results apply to all patients with a sore throat? The authors point out that the studies included patients primarily with severe or exudative tonsillopharyngitis. This ranged from 37% of 100% of patients in the studies. The authors found no evidence of effectiveness in studies in which the proportion of patients with exudates was <50%, suggesting caution in applying the results to less severely affected patients. In one Canadian study, only 17% of unselected sore throat patients had exudates. 1 As a result, these results may apply to as few as one in fi ve sore throat patients in general practice.
The interpretation of the pain relief outcomes is also perhaps not straightforward. Almost 3 times as many patients reported complete pain resolution at 24 h compared with placebo. At 48 h, 76% of cortico steroid patients had complete pain relief, but so did 47% of placebo patients. On average, the mean time to pain relief was 5 h earlier in the corticosteroid-treated group. Was this benefi t considered important by patients? Were there differences in the proportions of patients in each group satisfi ed with their pain relief at 24 or 48 h or on returning to normal function? In the studies in which days missed from work or school were reported, no signifi cant differences were found. Also, although analgesic medications were allowed, it is not clear what proportion of patients took analgesics or whether they were taken regularly and at an optimum dose. Thus, it remains unclear whether corticosteroids offer more effective pain relief than regularly used mild analgesics. However, even a small benefi t might be valued by patients, as long as risks are minimal. Unfortunately, only one of the eight studies reported adverse events. Although the authors point out that the risks for brief corticosteroid therapy are considered acceptable in croup or asthma, treatment in these conditions may prevent a hospitalisation for respiratory distress. The benefi t here is avoiding having to wait an extra 5 h for pain relief. With millions of visits for sore throat each year, 2 even rare but serious events could be important if this treatment were widely adopted. In this regard, high-quality safety data are needed.
Warren McIsaac
Can corticosteroids fi ll the therapeutic vacuum left by reduced antibiotic prescribing? As the authors point out, this meta-analysis cannot answer this question, as all patients received antibiotics in addition to corticosteroids. Although the authors contend that antibiotics are no longer justifi ed to prevent complications such as rheumatic fever, the American Heart Association and the American Academy of Pediatrics continue to support the primary prevention of rheumatic fever through the use of antibiotics for group A β-haemolytic streptococcal tonsillopharyngitis in children. 3 In adults, they advise testing for group A β-haemolytic streptococcus to limit unnecessary antibiotic use in sore throat.
How, then, should these results be applied in practice? The meta-analysis found no evidence for adding corticosteroids to antibiotic treatment in exudative sore throat in children. Primary care practitioners may consider adding corticosteroids in the small proportion of adult patients with severe or exudative tonsillopharyngitis. However, the lack of data about adverse events means that patient values need to be assessed regarding the relative importance they place on an earlier onset of pain relief of perhaps 5 h compared with not being able to be assured there are no rare but serious adverse events. Patients also need to be informed that it is not known whether the same degree of pain relief could be achieved with regularly used mild analgesics taken at an optimum dose along with antibiotics. Importantly, this meta-analysis does not provide evidence for the use of corticosteroids instead of antibiotics in milder cases of sore throat or as a fi rst-line treatment for group A β-haemolytic streptococcus tonsillopharyngitis.
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